A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With Multi-Agent Chemotherapy as Frontline Therapy in Patients With Hodgkin Lymphoma

Trial Profile

A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With Multi-Agent Chemotherapy as Frontline Therapy in Patients With Hodgkin Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 10 Feb 2015 Results published in a Seattle Genetics Media Release.
    • 11 Oct 2013 Results were presented at the 9th International Symposium on Hodgkin Lymphoma (ISHL) according to a Seattle Genetics media release. Results were also summarised in the media release.
    • 10 Dec 2012 Results were presented at the 54th American Society of Hematology (ASH) Annual Meeting according to a Millennium media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top